Novartis
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Basel, Basel-Stadt, Switzerland, Europe
Region: Basel-Stadt
Country: CH
Continent: Europe
About
Novartis is a global innovative medicines company focused on discovering and developing therapies to improve and extend people’s lives. It conducts research and development across cardiovascular, metabolic, immunology, neuroscience, and oncology, with medicines reaching hundreds of millions of patients worldwide. The company emphasizes patient access, ESG commitments, and strategic collaborations to advance science and healthcare outcomes. Novartis also highlights expanding manufacturing and development capacity to scale innovation and patient impact globally.
Novartis is a Swiss multinational pharmaceutical company that discovers and develops innovative medicines to treat diseases in oncology, cardiovascular, immunology, and neuroscience. Its products include prescription drugs, generic medications, and diagnostic solutions, serving patients and healthcare providers globally. The firm operates research institutes and manufacturing facilities to scale i
Novartis AG
1996
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
Public Company
2494194394
over-1b
ipo
NYSE:NVS
nasdaq
Investors
Founders
Alexander Clavel
Joerg Reinhardt
Johann Rudolf
Shwen Gwee
Leadership
Peggy Carter — Director Regulatory Affairs
Michelle Chernock — Therapeutic Area Head for Neuroscience
Dejan Arzensek — Senior Manager
Mirjam Neelen — Head of Global Learning Design & Learning Sciences
Sonja Catrin Fabian — Global Head Talent Management & Leadership, Sandoz
Janneke van der Kamp — Head Region Europe
Shahram Ebadollahi — Chief Data and AI Officer
Joerg Reinhardt — board_member
Technology Stack
Products
Fabhalta®: A medication for patients with paroxysmal nocturnal hemoglobinuria (PNH) that improves hemoglobin levels.
Pluvicto™: A treatment for PSMA-positive metastatic hormone-sensitive prostate cancer that improves radiographic progression-free survival.
Kisqali®: A medication that reduces the risk of breast cancer recurrence in younger patients with early breast cancer.
Funding rounds
Post Ipo Debt · $2.49B · (2024-06-19)
Grant · $6.5M · (2018-02-14) · Lead: Bill & Melinda Gates Foundation
IPO · (2000-05-19)
Connect
Connect
Open positions(12)
- Data Scientist, AI for Biomedical ImagingFull-timeWork from OfficeCambridge (USA)126,000–234,000 / Year
- Data Scientist, AI for Biomedical ImagingFull-timeWork from OfficeCambridge (USA)126,000–234,000 / Year
- Principal Clinical Data ScientistFull-timeHybridEast Hanover119,700–222,300 / Year
- Principal Scientist, Structural BiologicsFull-timeWork from OfficeLaJolla/SD108,500–201,500 / Year
- Principal Scientist IIFull-timeWork from OfficeCambridge (USA)119,700–222,300 / Year
- Human Genetics Data ScientistFull-timeWork from OfficeCambridge (USA)103,600–192,400 / Year
- Human Genetics Data ScientistFull-timeWork from OfficeCambridge (USA)103,600–192,400 / Year
- Senior Principal Scientist - ProteomicsPremiumFull-timeWork from OfficeBasel (City)126’000–234’000 / Year
- Principal Clinical Data ScientistPremiumFull-timeHybridEast Hanover119,700–222,300 / Year
- Principal Scientist, Structural BiologicsPremiumFull-timeWork from OfficeLaJolla/SD108,500–201,500 / Year
- Principal Scientist IIFull-timeWork from OfficeCambridge (USA)119,700–222,300 / Year
- STG - AI SOLUTIONS & AUTOMATION ENGINEERPremiumInternshipWork from OfficeParis Headquarter (PHARMA)